|
Clinical Faculty and Staff Profiles: |
|
| Robert Adams, MD | |
| James Carroll, MD | |
| Morris Cohen, EdD | |
| Christiana Hall, MD | |
| David Hess, MD | |
| Mary Hughes, MD | |
|
Gregory Lee, PhD |
|
|
John Morgan, MD, PhD |
|
|
Anthony Murro, MD |
|
|
Fenwick
Nichols, MD |
|
|
Yong Park, MD |
|
|
Shirley
Poduslo, PhD |
|
|
Ned Pruitt, MD |
|
|
Michael Rivner,
MD |
|
|
Elizabeth Sekul, MD |
|
|
Kapil Sethi, MD |
|
|
Suzanne
Smith, MD |
|
|
Thomas Swift, MD |
|
|
Jeffrey Switzer, MD |
|
|
|
|
 |
Cesar V. Borlongan, Ph.D.Associate Professor, Department of Neurology Director, MCG Department of Neurology Cell Transplantation |
Training
- M.S., Psychology, University of the Philippines, 1986
- M.A., Clinical Psychology, University of the Philippines, 1990
- Ph.D., Physiological Psychology, Keio University, Tokyo, Japan, 1994
- Postdoctoral Fellow, Department of Neurosurgery, University of South
Florida College of Medicine, Tampa, Florida, 1993-1995 - Assistant Professor, Department of Neurosurgery, University of South
Florida College of Medicine, Tampa, Florida, 1995-1998 - Senior Staff Fellow, Intramural Research Program, NIDA, NIH, Maryland, 1998-2002
Clinical Interests
- Participated in establishing clinical trials of fetal neural transplantation therapy for Parkinson disease (University of South Florida College of Medicine, 1993-1995)
- Provided the scientific evidence for proceeding with the first world transplant therapy (using neuroteratocarinoma cells) in stroke patients (Layton Bioscience Inc, 1998)
- Development of spheramine retinal pigmented epithelial cell transplants in Parkinson disease (Titan Pharmaceuticals, currently in clinical trials)
- Providing preclinical evidence of therapeutic effects of
transplantation of porcine choroid plexus (DiatraNZ and LCT Biopharma)
cyclosporine-A (Maas BiolAB) in neurological disorders.
Research Interests
- Advancing cell transplantation therapy for stroke, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, epilepsy and other neurological disorders
- Human-derived stem and progenitor cells that have been genetically engineered using viral vectors are currently being examined using in vivo and cell/tissue culture models of these human disorders
- The therapeutic effects of immunosuppressants, neurotrophic factors, free radical scavengers, and cognitive enhancers, as well as "enriched environment" are also being studied to improve transplantation functional outcomes
- The goal is to elucidate neuronal mechanisms underlying brain
injury/degeneration and, in turn, exploit these neuronal pathways via
transplantation therapy to induce protection and/or regeneration in
diseased or aging brain
Publications List (PubMED)
Contact
Department of Neurology
Medical College of Georgia
1120 15th Street
Augusta, GA 30912
Lab Address
Augusta Veterans Affairs Medical Center
VA-5B140
Office phone: (706) 733-0188 Ext. 2484/2485
Email: cborlongan@mcg.edu